Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database

CONCLUSION: Our findings suggest a potential consideration for repurposing anti-diabetic weight loss-inducing drugs including semaglutide, dulaglutide, and liraglutide (glucagon-like peptide-1 receptor agonists), empagliflozin (sodium-glucose cotransporter-2 inhibitor), and metformin (biguanide), for MS. This warrants validation through rigorous methodologies and prospective studies.PMID:38566910 | PMC:PMC10986166 | DOI:10.1177/17562864241241383
Source: Adv Data - Category: Epidemiology Authors: Source Type: research